Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Mutations in GFAP Disrupt the Distribution and Function of Organelles in Human Astrocytes.

Jones JR, Kong L, Hanna MG 4th, Hoffman B, Krencik R, Bradley R, Hagemann T, Choi J, Doers M, Dubovis M, Sherafat MA, Bhattacharyya A, Kendziorski C, Audhya A, Messing A, Zhang SC.

Cell Rep. 2018 Oct 23;25(4):947-958.e4. doi: 10.1016/j.celrep.2018.09.083.

2.

AP-1 and the injury response of the GFAP gene.

Brenner M, Messing A, Olsen ML.

J Neurosci Res. 2019 Feb;97(2):149-161. doi: 10.1002/jnr.24338. Epub 2018 Oct 22.

PMID:
30345544
3.

Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease.

Wang L, Xia J, Li J, Hagemann TL, Jones JR, Fraenkel E, Weitz DA, Zhang SC, Messing A, Feany MB.

Nat Commun. 2018 May 15;9(1):1899. doi: 10.1038/s41467-018-04269-7.

4.

Alexander disease.

Messing A.

Handb Clin Neurol. 2018;148:693-700. doi: 10.1016/B978-0-444-64076-5.00044-2. Review.

PMID:
29478608
5.

Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.

Hagemann TL, Powers B, Mazur C, Kim A, Wheeler S, Hung G, Swayze E, Messing A.

Ann Neurol. 2018 Jan;83(1):27-39. doi: 10.1002/ana.25118. Epub 2018 Jan 14.

6.

Autism in Wisconsin–Is It Increasing, and What Can We Do About It?

Messing A, Golden RN.

WMJ. 2017 Feb;116(1):45-6. No abstract available.

7.

Characterization of a panel of monoclonal antibodies recognizing specific epitopes on GFAP.

Lin NH, Messing A, Perng MD.

PLoS One. 2017 Jul 10;12(7):e0180694. doi: 10.1371/journal.pone.0180694. eCollection 2017.

8.

Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease.

Moody LR, Barrett-Wilt GA, Sussman MR, Messing A.

J Biol Chem. 2017 Apr 7;292(14):5814-5824. doi: 10.1074/jbc.M116.772020. Epub 2017 Feb 21.

9.

The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP.

Lin NH, Huang YS, Opal P, Goldman RD, Messing A, Perng MD.

Mol Biol Cell. 2016 Dec 15;27(25):3980-3990. Epub 2016 Oct 26.

10.

An In Vivo Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System Disease.

Wang L, Hagemann TL, Messing A, Feany MB.

J Neurosci. 2016 Feb 3;36(5):1445-55. doi: 10.1523/JNEUROSCI.0256-15.2016.

11.

Astrocytes: a central element in neurological diseases.

Pekny M, Pekna M, Messing A, Steinhäuser C, Lee JM, Parpura V, Hol EM, Sofroniew MV, Verkhratsky A.

Acta Neuropathol. 2016 Mar;131(3):323-45. doi: 10.1007/s00401-015-1513-1. Epub 2015 Dec 15. Review.

PMID:
26671410
12.

Nitric oxide mediates glial-induced neurodegeneration in Alexander disease.

Wang L, Hagemann TL, Kalwa H, Michel T, Messing A, Feany MB.

Nat Commun. 2015 Nov 26;6:8966. doi: 10.1038/ncomms9966.

13.

CSF and Blood Levels of GFAP in Alexander Disease

Jany PL, Agosta GE, Benko WS, Eickhoff JC, Keller SR, Köehler W, Koeller D, Mar S, Naidu S, Marie Ness J, Pareyson D, Renaud DL, Salsano E, Schiffmann R, Simon J, Vanderver A, Eichler F, van der Knaap MS, Messing A.

eNeuro. 2015 Oct 1;2(5). pii: ENEURO.0080-15.2015. doi: 10.1523/ENEURO.0080-15.2015. eCollection 2015 Sep.

14.

Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease.

LaPash Daniels CM, Paffenroth E, Austin EV, Glebov K, Lewis D, Walter J, Messing A.

PLoS One. 2015 Sep 17;10(9):e0138132. doi: 10.1371/journal.pone.0138132. eCollection 2015.

15.

Disease specific therapies in leukodystrophies and leukoencephalopathies.

Helman G, Van Haren K, Bonkowsky JL, Bernard G, Pizzino A, Braverman N, Suhr D, Patterson MC, Ali Fatemi S, Leonard J, van der Knaap MS, Back SA, Damiani S, Goldman SA, Takanohashi A, Petryniak M, Rowitch D, Messing A, Wrabetz L, Schiffmann R, Eichler F, Escolar ML, Vanderver A; GLIA Consortium.

Mol Genet Metab. 2015 Apr;114(4):527-36. doi: 10.1016/j.ymgme.2015.01.014. Epub 2015 Feb 7.

16.

Effects of traumatic brain injury on reactive astrogliosis and seizures in mouse models of Alexander disease.

Cotrina ML, Chen M, Han X, Iliff J, Ren Z, Sun W, Hagemann T, Goldman J, Messing A, Nedergaard M.

Brain Res. 2014 Sep 25;1582:211-9. doi: 10.1016/j.brainres.2014.07.029. Epub 2014 Jul 25.

17.

A new mutation in GFAP widens the spectrum of Alexander disease.

Brenner M, Messing A.

Eur J Hum Genet. 2015 Jan;23(1):1-2. doi: 10.1038/ejhg.2014.99. Epub 2014 Jun 25. No abstract available.

18.

Astrocytic TDP-43 pathology in Alexander disease.

Walker AK, Daniels CM, Goldman JE, Trojanowski JQ, Lee VM, Messing A.

J Neurosci. 2014 May 7;34(19):6448-58. doi: 10.1523/JNEUROSCI.0248-14.2014.

19.

Deficits in adult neurogenesis, contextual fear conditioning, and spatial learning in a Gfap mutant mouse model of Alexander disease.

Hagemann TL, Paylor R, Messing A.

J Neurosci. 2013 Nov 20;33(47):18698-706. doi: 10.1523/JNEUROSCI.3693-13.2013.

20.

Caspase cleavage of GFAP produces an assembly-compromised proteolytic fragment that promotes filament aggregation.

Chen MH, Hagemann TL, Quinlan RA, Messing A, Perng MD.

ASN Neuro. 2013 Nov 19;5(5):e00125. doi: 10.1042/AN20130032.

21.

Transgenic analysis of GFAP promoter elements.

Yeo S, Bandyopadhyay S, Messing A, Brenner M.

Glia. 2013 Sep;61(9):1488-99. doi: 10.1002/glia.22536. Epub 2013 Jul 8.

22.
23.

Protein changes in immunodepleted cerebrospinal fluid from a transgenic mouse model of Alexander disease detected using mass spectrometry.

Cunningham R, Jany P, Messing A, Li L.

J Proteome Res. 2013 Feb 1;12(2):719-28. doi: 10.1021/pr300785h. Epub 2013 Jan 11.

24.

The effect of glial fibrillary acidic protein expression on neurite outgrowth from retinal explants in a permissive environment.

Toops KA, Hagemann TL, Messing A, Nickells RW.

BMC Res Notes. 2012 Dec 22;5:693. doi: 10.1186/1756-0500-5-693.

25.

Beneficial effects of Nrf2 overexpression in a mouse model of Alexander disease.

LaPash Daniels CM, Austin EV, Rockney DE, Jacka EM, Hagemann TL, Johnson DA, Johnson JA, Messing A.

J Neurosci. 2012 Aug 1;32(31):10507-15. doi: 10.1523/JNEUROSCI.1494-12.2012.

26.

Genetic ablation of Nrf2/antioxidant response pathway in Alexander disease mice reduces hippocampal gliosis but does not impact survival.

Hagemann TL, Jobe EM, Messing A.

PLoS One. 2012;7(5):e37304. doi: 10.1371/journal.pone.0037304. Epub 2012 May 31.

27.

Alexander disease.

Messing A, Brenner M, Feany MB, Nedergaard M, Goldman JE.

J Neurosci. 2012 Apr 11;32(15):5017-23. doi: 10.1523/JNEUROSCI.5384-11.2012. No abstract available.

28.

Splice site, frameshift, and chimeric GFAP mutations in Alexander disease.

Flint D, Li R, Webster LS, Naidu S, Kolodny E, Percy A, van der Knaap M, Powers JM, Mantovani JF, Ekstein J, Goldman JE, Messing A, Brenner M.

Hum Mutat. 2012 Jul;33(7):1141-8. doi: 10.1002/humu.22094. Epub 2012 Apr 30.

29.

Neurological diseases as primary gliopathies: a reassessment of neurocentrism.

Verkhratsky A, Sofroniew MV, Messing A, deLanerolle NC, Rempe D, Rodríguez JJ, Nedergaard M.

ASN Neuro. 2012 Apr 5;4(3). pii: e00082. doi: 10.1042/AN20120010. Review.

30.

Archetypal and new families with Alexander disease and novel mutations in GFAP.

Messing A, Li R, Naidu S, Taylor JP, Silverman L, Flint D, van der Knaap MS, Brenner M.

Arch Neurol. 2012 Feb;69(2):208-14. doi: 10.1001/archneurol.2011.1181. Epub 2011 Oct 10. Erratum in: Arch Neurol. 2012 May;69(5):643.

31.

GFAP mutations, age at onset, and clinical subtypes in Alexander disease.

Prust M, Wang J, Morizono H, Messing A, Brenner M, Gordon E, Hartka T, Sokohl A, Schiffmann R, Gordish-Dressman H, Albin R, Amartino H, Brockman K, Dinopoulos A, Dotti MT, Fain D, Fernandez R, Ferreira J, Fleming J, Gill D, Griebel M, Heilstedt H, Kaplan P, Lewis D, Nakagawa M, Pedersen R, Reddy A, Sawaishi Y, Schneider M, Sherr E, Takiyama Y, Wakabayashi K, Gorospe JR, Vanderver A.

Neurology. 2011 Sep 27;77(13):1287-94. doi: 10.1212/WNL.0b013e3182309f72. Epub 2011 Sep 14.

32.

Knockdown of MLC1 in primary astrocytes causes cell vacuolation: a MLC disease cell model.

Duarri A, Lopez de Heredia M, Capdevila-Nortes X, Ridder MC, Montolio M, López-Hernández T, Boor I, Lien CF, Hagemann T, Messing A, Gorecki DC, Scheper GC, Martínez A, Nunes V, van der Knaap MS, Estévez R.

Neurobiol Dis. 2011 Jul;43(1):228-38. doi: 10.1016/j.nbd.2011.03.015. Epub 2011 Apr 3.

33.

P0S63del impedes the arrival of wild-type P0 glycoprotein to myelin in CMT1B mice.

Fratta P, Saveri P, Zambroni D, Ferri C, Tinelli E, Messing A, D'Antonio M, Feltri ML, Wrabetz L.

Hum Mol Genet. 2011 Jun 1;20(11):2081-90. doi: 10.1093/hmg/ddr081. Epub 2011 Mar 1.

34.

Brain-specific Phgdh deletion reveals a pivotal role for L-serine biosynthesis in controlling the level of D-serine, an N-methyl-D-aspartate receptor co-agonist, in adult brain.

Yang JH, Wada A, Yoshida K, Miyoshi Y, Sayano T, Esaki K, Kinoshita MO, Tomonaga S, Azuma N, Watanabe M, Hamase K, Zaitsu K, Machida T, Messing A, Itohara S, Hirabayashi Y, Furuya S.

J Biol Chem. 2010 Dec 31;285(53):41380-90. doi: 10.1074/jbc.M110.187443. Epub 2010 Oct 21.

35.

Strategies for treatment in Alexander disease.

Messing A, LaPash Daniels CM, Hagemann TL.

Neurotherapeutics. 2010 Oct;7(4):507-15. doi: 10.1016/j.nurt.2010.05.013. Review.

36.

Inhibition of Na+/H+ exchanger isoform 1 is neuroprotective in neonatal hypoxic ischemic brain injury.

Cengiz P, Kleman N, Uluc K, Kendigelen P, Hagemann T, Akture E, Messing A, Ferrazzano P, Sun D.

Antioxid Redox Signal. 2011 May 15;14(10):1803-13. doi: 10.1089/ars.2010.3468. Epub 2010 Dec 4.

37.

Alteration of glial-neuronal metabolic interactions in a mouse model of Alexander disease.

Meisingset TW, Risa Ø, Brenner M, Messing A, Sonnewald U.

Glia. 2010 Aug;58(10):1228-34. doi: 10.1002/glia.21003.

38.

Drug screening to identify suppressors of GFAP expression.

Cho W, Brenner M, Peters N, Messing A.

Hum Mol Genet. 2010 Aug 15;19(16):3169-78. doi: 10.1093/hmg/ddq227. Epub 2010 Jun 10.

39.

Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes.

Tian R, Wu X, Hagemann TL, Sosunov AA, Messing A, McKhann GM, Goldman JE.

J Neuropathol Exp Neurol. 2010 Apr;69(4):335-45. doi: 10.1097/NEN.0b013e3181d3cb52.

40.

Dysfunctions of neuronal and glial intermediate filaments in disease.

Liem RK, Messing A.

J Clin Invest. 2009 Jul;119(7):1814-24. doi: 10.1172/JCI38003. Epub 2009 Jul 1. Review.

41.

Dual transgenic reporter mice as a tool for monitoring expression of glial fibrillary acidic protein.

Cho W, Hagemann TL, Johnson DA, Johnson JA, Messing A.

J Neurochem. 2009 Jul;110(1):343-51. doi: 10.1111/j.1471-4159.2009.06146.x. Epub 2009 May 5.

42.

Properties of astrocytes cultured from GFAP over-expressing and GFAP mutant mice.

Cho W, Messing A.

Exp Cell Res. 2009 Apr 15;315(7):1260-72. doi: 10.1016/j.yexcr.2008.12.012. Epub 2008 Dec 29.

43.

Suppression of GFAP toxicity by alphaB-crystallin in mouse models of Alexander disease.

Hagemann TL, Boelens WC, Wawrousek EF, Messing A.

Hum Mol Genet. 2009 Apr 1;18(7):1190-9. doi: 10.1093/hmg/ddp013. Epub 2009 Jan 7.

44.

Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis.

Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA.

J Neurosci. 2008 Dec 10;28(50):13574-81. doi: 10.1523/JNEUROSCI.4099-08.2008.

45.

Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways.

Tang G, Yue Z, Talloczy Z, Hagemann T, Cho W, Messing A, Sulzer DL, Goldman JE.

Hum Mol Genet. 2008 Jun 1;17(11):1540-55. doi: 10.1093/hmg/ddn042. Epub 2008 Feb 14.

46.

GFAP promoter elements required for region-specific and astrocyte-specific expression.

Lee Y, Messing A, Su M, Brenner M.

Glia. 2008 Apr;56(5):481-93. doi: 10.1002/glia.20622.

PMID:
18240313
47.
48.

Sleep in Kcna2 knockout mice.

Douglas CL, Vyazovskiy V, Southard T, Chiu SY, Messing A, Tononi G, Cirelli C.

BMC Biol. 2007 Oct 9;5:42.

49.

Seizures and reduced life span in mice lacking the potassium channel subunit Kv1.2, but hypoexcitability and enlarged Kv1 currents in auditory neurons.

Brew HM, Gittelman JX, Silverstein RS, Hanks TD, Demas VP, Robinson LC, Robbins CA, McKee-Johnson J, Chiu SY, Messing A, Tempel BL.

J Neurophysiol. 2007 Sep;98(3):1501-25. Epub 2007 Jul 18.

50.

GFAP and its role in Alexander disease.

Quinlan RA, Brenner M, Goldman JE, Messing A.

Exp Cell Res. 2007 Jun 10;313(10):2077-87. Epub 2007 Apr 6. Review.

Supplemental Content

Loading ...
Support Center